OHSU News

This email notification is intended as a heads up to OHSU communicators. It is not shared with external subscribers.

OHSU Doernbecher patient first human to receive trial therapy for rare, devastating form of epilepsy

OHSU Doernbecher patient first human to receive trial therapy for rare, devastating form of epilepsy

Multi-site phase 1/2a clinical study works to assess safety, dosage of promising drug to treat Dravet syndrome.